細胞・遺伝子治療製造品質管理（QC）市場- 世界の産業規模、シェア、動向、機会、予測、治療タイプ別、提供別、プロセス別、技術別、用途別、地域別、競合別セグメント、2019-2029年

細胞・遺伝子治療製造品質管理（QC）の世界市場規模は2023年に10億4,000万米ドルとなり、2029年までのCAGRは6.85%で、予測期間中に着実な成長が予測されています。

世界の細胞・遺伝子治療製造品質管理（QC）市場は、細胞・遺伝子治療製品の安全性、有効性、信頼性を確保することに焦点を当てた急速に発展している分野を包含しています。品質管理は、厳格な規制基準を満たすための厳格な試験と製造プロトコルの検証を含む、製造プロセスにおける重要な要素です。QC市場は、複雑な疾患をターゲットとする高度な治療に対する急増する需要に牽引されており、分析とプロセスの標準化のための最先端技術に大きく依存しています。

市場促進要因

がんと心血管疾患の有病率の上昇

医薬品研究開発の成長

治療薬のパイプラインの増加

製造のスケールアップ

主な市場課題

遺伝子・細胞治療薬の高度製造と品質管理に熟練した専門家の不足

品質管理コストの高さ

主な市場動向

QA基準の厳格な遵守

QCシステムにおけるAIなどの技術の利用

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の細胞・遺伝子治療製造品質管理（QC）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別（細胞治療、遺伝子治療）
  • 提供別（機器、消耗品、その他）
  • 工程別（原材料準備、上流工程、下流工程、包装）
  • 技術別（ポリメラーゼ連鎖反応（PCR）、フローサイトメトリー、リムルスアメーバ細胞溶解液（LAL）、酵素免疫測定法（ELISA）、クロマトグラフィー、質量分析、ウェスタンブロッティング、次世代シーケンシング（NGS）、電気泳動、その他）
  • 用途別（安全性試験、効力試験、同一性試験、安定性および遺伝的忠実性試験、その他）
  • 地域別
  • 企業別（2023）
• 市場マップ

第5章 北米の細胞・遺伝子治療製造品質管理（QC）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 提供別
  • プロセス別
  • 技術別
  • 用途別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第6章 欧州の細胞・遺伝子治療製造品質管理（QC）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 提供別
  • プロセス別
  • 技術別
  • 用途別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第7章 アジア太平洋地域の細胞・遺伝子治療製造品質管理（QC）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 提供別
  • プロセス別
  • 技術別
  • 用途別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第8章 南米の細胞・遺伝子治療製造品質管理（QC）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 提供別
  • プロセス別
  • 技術別
  • 用途別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの細胞・遺伝子治療製造品質管理（QC）市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療の種類別
  • 提供別
  • プロセス別
  • 技術別
  • 用途別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 合併および買収（該当する場合）
• 製品の発売（ある場合）
• 最近の動向

第12章 PESTEL分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Bio-Techne Corporation
• Biomerieux SA
• F. Hoffmann-La Roche Ltd
• Lonza Group Ltd.
• Miltenyi Biotec India Pvt Ltd.
• Sartorius AG
• Thermo Fisher Scientific Inc.
• AGC Inc.
• Charles River Laboratories International, Inc.
• Merck KGaA

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Cell and Gene Therapy Manufacturing QC Market was valued at USD 1.04 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 6.85% through 2029. The Global Cell and Gene Therapy Manufacturing Quality Control (QC) market encompasses the rapidly evolving sector focused on ensuring the safety, efficacy, and reliability of cell and gene therapy products. Quality control is a critical component in the production process, involving rigorous testing and validation of manufacturing protocols to meet strict regulatory standards. The QC market is driven by the burgeoning demand for advanced therapies targeting complex diseases and relies heavily on cutting-edge technologies for analytics and process standardization.

Key Market Drivers

Rise in Prevalence of Cancer & Cardiovascular Diseases

Cell therapy focuses on different illnesses at the cellular level, either by rejuvenating a specific cell group or by utilizing cells as carriers for therapeutic agents. Whereas gene therapy seeks to impact the progression of various genetic and acquired conditions at the genetic level. It is expected that cardiovascular ailments will propel the demand for cell and gene therapies which will in turn drive the growth of cell and gene therapy manufacturing QC market in the forecast period. One possible treatment which have emerged as a leading option for management of cardiac arrhythmias are approaches which can improve the action potential conduction and electrical excitability in the heart.

Stem cell therapy has the significant potential to treat cardiac diseases mainly heart failure and coronary heart diseases. Numerous clinical trials have depicted that stem cell therapies are safe to use and acquire the extensive capability to improve the heart function thereby reducing the chances of adverse cardiovascular events. Cancer have also prevailed as a leading morbidity over past few years. In two latest clinical trials which were conducted in 2022, it has been proved that CAR T-cell therapy can also be used for management of non-Hodgkin lymphoma in patients whose cancer returned after initial stage. Therefore, development of new cell and new therapies which are making new additions in treatment techniques of serious chronic diseases are also anticipated to bolster the growth of cell and gene therapy manufacturing QC market in the forecast period.

Growth in Pharmaceutical Research & Development

Cell and gene therapies are a rapidly expanding domain of medicine with the capability to cure a broad spectrum of ailments. Nevertheless, these therapies are also inherently complex and require rigorous quality assurance (QA) measures to ensure their well-being and effectiveness. Research and development in the quality control of cell and gene therapies is concentrated on developing novel approaches and technologies that can enhance the precision, effectiveness, and promptness of quality control testing. Many new methods have been developed in recent years to facilitate the QC of cell and gene therapies. Scientists at the University of Pennsylvania created a novel technique for characterizing the efficacy of cellular and genetic treatments. This technique is known as functional evaluations which enables the quantification of cells' capacity to carry out designated functions, such as combating infections or generating proteins.

Increasing Pipeline of Therapies

The burgeoning pipeline of innovative therapies, particularly in the realm of cell and gene therapy, is catalyzing a surge in demand for robust quality control (QC) solutions worldwide. With an increasing number of biopharmaceutical companies focusing on developing cutting-edge cell and gene therapies to address a diverse array of diseases, there's a pressing need for stringent QC measures to ensure safety, efficacy, and consistency of these treatments. The complexity of cell and gene therapies, often tailored to individual patients, necessitates meticulous QC protocols throughout the manufacturing process. T

he demand for specialized QC technologies and services tailored to the unique requirements of cell and gene therapy manufacturing is on the rise. This trend is driving significant growth in the global Cell and Gene Therapy Manufacturing QC Market, as companies seek reliable QC solutions to navigate the intricate regulatory landscape and bring innovative therapies to market efficiently and safely.

Manufacturing Scale-up

The process of scaling up manufacturing operations for cell and gene therapies is presenting a formidable challenge, one that significantly amplifies the demand for robust quality control (QC) solutions on a global scale. As promising therapies progress from early-stage development to commercial production, the need for stringent QC measures becomes paramount to ensure product quality, safety, and consistency at larger scales. Manufacturing scale-up introduces complexities such as optimizing production processes, increasing batch sizes, and maintaining uniformity across multiple manufacturing sites-all of which require meticulous QC protocols. Consequently, biopharmaceutical companies are increasingly investing in advanced QC technologies and expertise tailored specifically for cell and gene therapy manufacturing. This surge in demand for QC solutions is propelling the growth of the global Cell and Gene Therapy Manufacturing QC Market, as companies strive to meet regulatory requirements, minimize risks, and accelerate the commercialization of life-saving therapies.

Key Market Challenges

Shortage Of Professionals Skilled in Advanced Manufacturing & Quality Control of Gene & Cell Therapies

Strict adherence to quality assurance (QA) standards within the cell and gene therapy manufacturing sector may paradoxically decrease the demand for traditional quality control (QC) solutions globally. As regulatory agencies enforce stringent QA requirements to ensure the safety and efficacy of therapies, companies are compelled to implement comprehensive QA measures throughout the manufacturing process. This robust QA framework often incorporates built-in quality control mechanisms, reducing the need for separate QC systems. Advancements in manufacturing technologies and process optimization allow for greater consistency and reliability, minimizing the occurrence of errors and deviations that typically necessitate extensive QC interventions. There may be a shift towards integrated QA-QC approaches, where QC functions are seamlessly embedded within QA processes, leading to a potential decrease in the demand for standalone QC solutions in the cell and gene therapy manufacturing market as companies prioritize holistic quality assurance strategies.

High Cost of Quality Control

The high cost associated with quality control (QC) processes in cell and gene therapy manufacturing could potentially decrease the demand for QC solutions globally. While QC is crucial for ensuring the safety, efficacy, and consistency of therapies, the significant expenses involve. The complexity of cell and gene therapies, often requiring specialized QC technologies and expertise, can further inflate the costs of QC implementation and maintenance. Companies might opt to prioritize cost-saving measures or alternative QC strategies, such as outsourcing QC functions or utilizing less expensive QC technologies, potentially leading to a decreased demand for traditional QC solutions in the cell and gene therapy manufacturing market. This cost-conscious approach could shape the dynamics of the QC market as companies balance the need for quality assurance with financial constraints.

Key Market Trends

Strict Adherence to QA Standards

The stringent adherence to quality assurance (QA) standards within the cell and gene therapy manufacturing sector is playing a pivotal role in driving the demand for advanced quality control (QC) solutions on a global scale. As regulatory agencies impose rigorous requirements to ensure the safety, efficacy, and consistency of these groundbreaking therapies, biopharmaceutical companies are under increasing pressure to implement comprehensive QA measures throughout the manufacturing process. Strict adherence to QA standards necessitates robust QC protocols to detect and mitigate any deviations or discrepancies promptly. Consequently, there's a growing demand for specialized QC technologies and services tailored specifically for the unique challenges of cell and gene therapy manufacturing. This escalating demand for QC solutions is fueling the expansion of the global Cell and Gene Therapy Manufacturing QC Market as companies prioritize compliance with QA standards to navigate regulatory complexities, uphold product quality, and accelerate the development and commercialization of transformative therapies.

Use of Technologies like AI In QC Systems

The integration of cutting-edge technologies, such as artificial intelligence (AI), into quality control (QC) systems, is revolutionizing the cell and gene therapy manufacturing landscape and significantly bolstering the demand for advanced QC solutions worldwide. AI-powered QC systems offer unprecedented capabilities for data analysis, predictive modeling, and real-time monitoring, enabling biopharmaceutical companies to enhance the efficiency, accuracy, and reliability of their QC processes. By leveraging AI algorithms to analyze vast datasets and identify patterns or anomalies, these systems can streamline QC protocols, accelerate decision-making, and mitigate risks during the manufacturing of complex cell and gene therapies. There's a surging demand for AI-driven QC technologies and services tailored specifically for the unique requirements of cell and gene therapy manufacturing. This increasing reliance on AI in QC systems is driving the growth of the global Cell and Gene Therapy Manufacturing QC Market as companies recognize the transformative potential of technology to optimize production processes, ensure regulatory compliance, and expedite the development and commercialization of innovative therapies.

Segmental Insights

Therapy Type Insights

Based on Therapy Type, gene therapy has gained rapid growth in the global cell and gene therapy manufacturing quality control (QC) market in 2023. This growing trend can be attributed to several factors. The increasing approval of gene therapy products by regulatory authorities has provided a strong foundation for the sector's expansion. Substantial investments in research and development (R&D) have fuelled advancements in gene therapy, leading to breakthrough treatments and therapies. The rising demand for regenerative medicine has further fuelled the growth of gene therapy as it offers the potential to address the root causes of genetic disorders. The impact of gene therapies goes beyond conventional treatments, as they are revolutionizing the fight against previously untreatable conditions.

By targeting the underlying genetic mechanisms, gene therapies offer new hope and possibilities for patients who have long struggled with debilitating disorders. This revolutionary approach has garnered significant interest from both the public and private sectors, driving further investment and research in this field. As the field of gene therapy continues to evolve, it holds immense promise for the future of medicine. With ongoing advancements, we can look forward to more targeted and effective treatments that could potentially transform the lives of countless individuals worldwide.

Offering Insights

Based on the Offering, within the global Cell and Gene Therapy Manufacturing Quality Control (QC) market, the Instruments segment is currently dominating in terms of market share. Cell and gene therapy manufacturing entails complex processes that demand precise quality control measures at each stage. Instruments are vital in guaranteeing the quality, purity, and effectiveness of therapeutic products, rendering them indispensable for manufacturers. Regulatory bodies impose rigorous quality control standards to ensure the safety and efficacy of cell and gene therapy products. Instruments provide dependable and standardized methodologies to meet these regulatory requirements, making them indispensable for achieving compliance and securing market approval. The rapid progress of technology has spurred the creation of advanced instruments tailored specifically for cell and gene therapy manufacturing QC. These instruments offer heightened sensitivity, accuracy, and throughput, empowering manufacturers to identify and rectify quality issues more efficiently. Automation plays a pivotal role in optimizing manufacturing processes and minimizing human error. Instruments equipped with automation capabilities facilitate streamlined sample processing, data analysis, and reporting, thereby enhancing overall QC effectiveness and productivity.

Regional Insights

North America has firmly established itself as the dominating region in the global market for cell and gene therapy manufacturing quality control (QC). This leadership position can be attributed to its highly advanced biotechnology infrastructure, which includes state-of-the-art research facilities, cutting-edge manufacturing capabilities, and a robust talent pool of scientists and experts. Substantial investments in research and development have propelled North America to the forefront of innovation in this field.

North America boasts a comprehensive regulatory framework that ensures the highest standards of safety and efficacy in therapeutic practices. These regulatory frameworks, meticulously designed and continuously updated, provide a solid foundation for the development and manufacturing of cell and gene therapies. The stringent regulations and rigorous quality control measures in place inspire confidence in the safety and effectiveness of these therapies, not only within North America but also internationally.

With its unwavering commitment to excellence and continuous advancements in technology, North America continues to raise the bar in the field of cell and gene therapy manufacturing quality control. The region's relentless pursuit of breakthroughs, coupled with its collaborative ecosystem of academia, industry, and regulatory bodies, fosters a fertile ground for innovation and ensures that North America remains at the forefront of this rapidly evolving field.

Regional Insights

In January 2023, Bio-Techne Corporation launched MauriceFlex, a novel addition to its ProteinSimple product line. MauriceFlex is a versatile platform designed to facilitate the separation of protein charge variants, expanding upon standard cIEF (capillary isoelectric focusing) and CE-SDS (capillary electrophoresis-sodium dodecyl sulfate) tests. This innovative system provides comprehensive protein characterization, streamlining examination procedures.

Regional Insights

Bio-Techne Corporation

Biomerieux SA

F. Hoffmann-La Roche Ltd

Lonza Group Ltd.

Miltenyi Biotec India Pvt Ltd.

Sartorius AG

Thermo Fisher Scientific Inc.

AGC Inc.

Charles River Laboratories International, Inc.

Merck KGaA

Report Scope:

In this report, the Global Cell and Gene Therapy Manufacturing QC Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cell and Gene Therapy Manufacturing QC Market, By Therapy Type:

Cell Therapy Gene Therapy

Cell and Gene Therapy Manufacturing QC Market, By Offering:

Instruments Consumables Others

Cell and Gene Therapy Manufacturing QC Market, By Process:

Raw Material Preparation Upstream Processing Downstream Processing Packaging

Cell and Gene Therapy Manufacturing QC Market, By Technology:

Polymerase Chain Reaction (PCR) Flow Cytometry Limulus Amebocyte Lysate (LAL) Enzyme-Linked Immunosorbent Assay (ELISA) Chromatography Mass Spectrometry Western Blotting Next-Generation Sequencing (NGS) Electrophoresis Others

Cell and Gene Therapy Manufacturing QC Market, By Application:

Safety Testing Potency Testing Identity Testing Stability and Genetic Fidelity Testing Others

Cell and Gene Therapy Manufacturing QC Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cell and Gene Therapy Manufacturing QC Market.

Available Customizations:

Global Cell and Gene Therapy Manufacturing QC Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Cell and Gene Therapy Manufacturing QC Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Therapy Type (Cell Therapy, Gene Therapy)
  • 4.2.2. By Offering (Instruments, Consumables, Others)
  • 4.2.3. By Process (Raw Material Preparation, Upstream Processing, Downstream Processing, Packaging)
  • 4.2.4. By Technology (Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), Electrophoresis, Others)
  • 4.2.5. By Application (Safety Testing, Potency Testing, Identity Testing, Stability and Genetic Fidelity Testing, Others)
  • 4.2.6. By Region
  • 4.2.7. By Company (2023)
• 4.3. Market Map

5. North America Cell and Gene Therapy Manufacturing QC Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapy Type
  • 5.2.2. By Offering
  • 5.2.3. By Process
  • 5.2.4. By Technology
  • 5.2.5. By Application
  • 5.2.6. By Country
• 5.3. North America: Country Analysis
  • 5.3.1. United States Cell and Gene Therapy Manufacturing QC Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Therapy Type
      • 5.3.1.2.2. By Offering
      • 5.3.1.2.3. By Process
      • 5.3.1.2.4. By Technology
      • 5.3.1.2.5. By Application
  • 5.3.2. Mexico Cell and Gene Therapy Manufacturing QC Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Therapy Type
      • 5.3.2.2.2. By Offering
      • 5.3.2.2.3. By Process
      • 5.3.2.2.4. By Technology
      • 5.3.2.2.5. By Application
  • 5.3.3. Canada Cell and Gene Therapy Manufacturing QC Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Therapy Type
      • 5.3.3.2.2. By Offering
      • 5.3.3.2.3. By Process
      • 5.3.3.2.4. By Technology
      • 5.3.3.2.5. By Application

6. Europe Cell and Gene Therapy Manufacturing QC Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapy Type
  • 6.2.2. By Offering
  • 6.2.3. By Process
  • 6.2.4. By Technology
  • 6.2.5. By Application
  • 6.2.6. By Country
• 6.3 Europe: Country Analysis
  • 6.3.1. France Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapy Type
      • 6.3.1.2.2. By Offering
      • 6.3.1.2.3. By Process
      • 6.3.1.2.4. By Technology
      • 6.3.1.2.5. By Application
  • 6.3.2. Germany Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapy Type
      • 6.3.2.2.2. By Offering
      • 6.3.2.2.3. By Process
      • 6.3.2.2.4. By Technology
      • 6.3.2.2.5. By Application
  • 6.3.3. United Kingdom Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapy Type
      • 6.3.3.2.2. By Offering
      • 6.3.3.2.3. By Process
      • 6.3.3.2.4. By Technology
      • 6.3.3.2.5. By Application
  • 6.3.4. Italy Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapy Type
      • 6.3.4.2.2. By Offering
      • 6.3.4.2.3. By Process
      • 6.3.4.2.4. By Technology
      • 6.3.4.2.5. By Application
  • 6.3.5. Spain Cell and Gene Therapy Manufacturing QC Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapy Type
      • 6.3.5.2.2. By Offering
      • 6.3.5.2.3. By Process
      • 6.3.5.2.4. By Technology
      • 6.3.5.2.5. By Application

7. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapy Type
  • 7.2.2. By Offering
  • 7.2.3. By Process
  • 7.2.4. By Technology
  • 7.2.5. By Application
  • 7.2.6. By Country
• 7.3. Asia-Pacific: Country Analysis
  • 7.3.1. China Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapy Type
      • 7.3.1.2.2. By Offering
      • 7.3.1.2.3. By Process
      • 7.3.1.2.4. By Technology
      • 7.3.1.2.5. By Application
  • 7.3.2. India Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapy Type
      • 7.3.2.2.2. By Offering
      • 7.3.2.2.3. By Process
      • 7.3.2.2.4. By Technology
      • 7.3.2.2.5. By Application
  • 7.3.3. South Korea Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapy Type
      • 7.3.3.2.2. By Offering
      • 7.3.3.2.3. By Process
      • 7.3.3.2.4. By Technology
      • 7.3.3.2.5. By Application
  • 7.3.4. Japan Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapy Type
      • 7.3.4.2.2. By Offering
      • 7.3.4.2.3. By Process
      • 7.3.4.2.4. By Technology
      • 7.3.4.2.5. By Application
  • 7.3.5. Australia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapy Type
      • 7.3.5.2.2. By Offering
      • 7.3.5.2.3. By Process
      • 7.3.5.2.4. By Technology
      • 7.3.5.2.5. By Application

8. South America Cell and Gene Therapy Manufacturing QC Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapy Type
  • 8.2.2. By Offering
  • 8.2.3. By Process
  • 8.2.4. By Technology
  • 8.2.5. By Application
  • 8.2.6. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapy Type
      • 8.3.1.2.2. By Offering
      • 8.3.1.2.3. By Process
      • 8.3.1.2.4. By Technology
      • 8.3.1.2.5. By Application
  • 8.3.2. Argentina Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapy Type
      • 8.3.2.2.2. By Offering
      • 8.3.2.2.3. By Process
      • 8.3.2.2.4. By Technology
      • 8.3.2.2.5. By Application
  • 8.3.3. Colombia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapy Type
      • 8.3.3.2.2. By Offering
      • 8.3.3.2.3. By Process
      • 8.3.3.2.4. By Technology
      • 8.3.3.2.5. By Application

9. Middle East and Africa Cell and Gene Therapy Manufacturing QC Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapy Type
  • 9.2.2. By Offering
  • 9.2.3. By Process
  • 9.2.4. By Technology
  • 9.2.5. By Application
  • 9.2.6. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapy Type
      • 9.3.1.2.2. By Offering
      • 9.3.1.2.3. By Process
      • 9.3.1.2.4. By Technology
      • 9.3.1.2.5. By Application
  • 9.3.2. Saudi Arabia Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapy Type
      • 9.3.2.2.2. By Offering
      • 9.3.2.2.3. By Process
      • 9.3.2.2.4. By Technology
      • 9.3.2.2.5. By Application
  • 9.3.3. UAE Cell and Gene Therapy Manufacturing QC Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Therapy Type
      • 9.3.3.2.2. By Offering
      • 9.3.3.2.3. By Process
      • 9.3.3.2.4. By Technology
      • 9.3.3.2.5. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Merger & Acquisition (If Any)
• 11.2. Product Launches (If Any)
• 11.3. Recent Developments

12. PESTLE Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Bio-Techne Corporation
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Biomerieux SA
• 14.3. F. Hoffmann-La Roche Ltd
• 14.4. Lonza Group Ltd.
• 14.5. Miltenyi Biotec India Pvt Ltd.
• 14.6. Sartorius AG
• 14.7. Thermo Fisher Scientific Inc.
• 14.8. AGC Inc.
• 14.9. Charles River Laboratories International, Inc.
• 14.10. Merck KGaA

15. Strategic Recommendations

16. About Us & Disclaimer